Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 a
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
04:15pm, Sunday, 02'nd Feb 2025
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal secu
NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal secu
The Schall Law Firm Invites Investors With Losses To Lead A Securities Fraud Case Against Pacira BioSciences, Inc.
11:00am, Sunday, 02'nd Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc.
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal secu
Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX
07:13am, Sunday, 02'nd Feb 2025
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal secu
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pac
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal secu
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ:PCRX) between August 2,
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ:PCRX). Such
LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc.
NEW ORLEANS , Jan. 31, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14,
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal secu
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
05:41pm, Friday, 31'st Jan 2025
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and Augus
